title: Development and application of a synthetic peptide-based osteocalcin assay for the measurement of bone formation in mouse serum.
abstract: The mouse is frequently used as an animal model to study skeletal mechanisms relevant to humans. Biochemical markers of bone formation and resorption provide one of the key parameters for assessing skeletal metabolism. One biochemical marker that has proven to be useful in the studies of mouse skeletal metabolism is osteocalcin. Assay for osteocalcin is available in the mouse. The present study describes development of an osteocalcin radioimmunoassay (RIA) using a synthetic peptide. Intact osteocalcin purified from mouse bone extracts shows parallel displacement with synthetic peptide. Sensitivity of the RIA was 19 ng/ml. The average (n = 9) intra- and interassay coefficient of variation for two controls was less than 10%; the averaged recoveries were 106%. The osteocalcin concentration measured by peptide RIA shows a high correlation (r = 0.88, n = 117, P < 0.0001) with an intact osteocalcin assay. In addition, when the intact assay and peptide assays were applied to evaluate skeletal perturbation, similar results were obtained. Accordingly, osteocalcin levels measured by both intact and peptide-based RIA in 8-week C57BL/6J (n = 8) mice treated with PTH 1-34 were twofold higher compared with the vehicle-treated control group. Further studies of the application of the peptide-based RIA for osteocalcin revealed that osteocalcin levels in 4-week postovariectomized (OVX) C57BL/6N mice (n = 10) were 80% higher than the sham-operated (n = 10) mice receiving vehicle. OVX mice receiving weekly injections of estradiol (400 microg/kg body weight) were 38% lower compared with the OVX group treated with vehicle. In conclusion, the peptide-based RIA has analytical and a discriminative power similar to that of the intact osteocalcin assay but has the advantage that the resources for this assay are much easier to accrue.
authors.affiliation: Musculoskeletal Disease Center, Jerry L. Pettis VA Medical Center, 11201 Benton Street (MC 151), and Loma Linda University, Loma Linda, California, USA.
authors.forename: A K
authors.initials: AK
authors.lastname: Srivastava
authors.forename: G
authors.initials: G
authors.lastname: Castillo
authors.forename: J E
authors.initials: JE
authors.lastname: Wergedal
authors.forename: S
authors.initials: S
authors.lastname: Mohan
authors.forename: D J
authors.initials: DJ
authors.lastname: Baylink
mesh_terms: D000818:Animals; D000918:Antibody Specificity; D015519:Bone Density / Q000502:physiology; D001846:Bone Development / Q000187:drug effects / Q000502:physiology*; D004195:Disease Models, Animal; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D015675:Osteocalcin / Q000097:blood* / Q000276:immunology; D010052:Ovariectomy; D010281:Parathyroid Hormone / Q000494:pharmacology; D010446:Peptide Fragments / Q000097:blood* / Q000276:immunology; D011863:Radioimmunoassay / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D010281:Parathyroid Hormone; D010446:Peptide Fragments; D015675:Osteocalcin; D004958:Estradiol